T cell recognition of an HLA-A2-restricted epitope derived from a cleaved signal sequence by unknown
Brief Detlnitive Report 
T  Cell  Recognition  of an HLA-A2-restricted  Epitope 
Derived from  a  Cleaved Signal  Sequence 
By Maryse Gu6guen, William E. Biddison,* and Eric O. Long 
From the Laboratory of Immunogenetics, National Institute of Allergy  and Infectious Diseases, 
National  Institutes of Health,  Rockville, Maryland 20852;  and the  *Neuroimmunology Branch, 
National Institute of Neurological Diseases and Stroke, National Institutes of Health,  Betkesda, 
Maryland 20892 
Summary 
An alternative pathway for class I-restricted antigen presentation has been suggested on the basis 
of peptides bound to HLA-A2 molecules in cells lacking the transporter for antigen presentation 
(TAP).  Most of these peptides were derived from signal sequences for translocation into the 
endoplasmic reticulum (ER). However, it is not known whether these peptides can be presented 
to T  cells. The hydrophobic nature of an HLA-A2-restricted T  cell epitope (M1  58-66)  was 
exploited to test whether it could be presented to T cells when derived from a signal sequence. 
Replacing the signal sequence of the influenza virus hemagglutinin molecule H3 with an artificial 
sequence containing that HLA-A2-restricted T  cell epitope resulted in efficient translocation 
of H3 molecules into the ER and transport to the cell surface. This signal sequence-derived epitope 
was presented to HLA-A2-restricted T cells. Involvement of cytosolic processing for this presentation 
is very unlikely, because (a) presentation occurred in cells lacking TAP; (b) expression of H3 
molecules with the artificial  signal sequence did not produce a detectable cytosolic form of H3; 
and (c) presentation of the same epitope expressed in cytosolic forms of antigen required TAP. 
Thus,  a peptide derived from a signal sequence cleaved in the ER can provide an epitope for 
HLA-A2-restricted T  cell recognition. 
C 
Ytosolic proteins constitute the major source ofpeptides 
for class I-restricted presentation to T  cells.  Peptides 
produced in the cytosol are transported to the early exocytic 
pathway where they bind to newly synthesized MHC class 
I molecules. Proper assembly of class I molecules and their 
transport to the cell surface require binding of peptide (1). 
Efficient delivery of cytosolic peptides into the endoplasmic 
reticulum (ER) requires an ATP-dependent transporter for 
antigen presentation (TAP). TAP-deficient mice express greatly 
reduced cell surface levels of MHC class I molecules and fail 
to  establish  a  normal  CD8 +  T  cell  repertoire  (2).  An 
inefficient, ATP-independent peptide transport into the EP, 
has been observed in the absence of TAP (3-5). Presentation 
of cytosolic peptides to class I-restricted T  cells can be de- 
tected in the absence of TAP (6), but is improved by attach- 
ment of a signal sequence for ER translocation (7-9). 
Cell surface expression of HLA-A2 is much less depen- 
dent on TAP than that of other class I alleles (10). Analysis 
of peptides eluted from HLA-A2 molecules in TAP-defective 
cells revealed that most were derived from signal sequences 
(11, 12). Similar peptides were also detected among peptides 
eluted from HLA-A2 in wild-type cells (12). However, the 
unusual length of these class I-bound peptides makes them 
poor candidates for T  cell epitopes (13). Although T  cells 
may recognize specific endogenous peptides bound to HLA-A2 
molecules in TAP-deficient cells, it is not known whether 
such peptides are derived from signal sequences (14). On the 
other hand, signal sequence-derived peptides can provide T 
cell epitopes in normal cells (15,  16). Furthermore, several 
peptides with nine residues,  derived from signal sequences, 
were eluted from HLA-B7 molecules in wild-type cells (17). 
It is possible that these signal sequence-derived peptides origi- 
nated  from processing  in  the cytosol,  given  the extreme 
efficiency  of the  class  I  processing  pathway.  Even  a  few 
precursor molecules that fail to translocate into the ER. may 
provide sufficient cytosolic peptides derived from their signal 
sequence. 
Thus, an important question remains: can signal sequence 
cleavage in the ER generate T  cell epitopes from leader se- 
quences? Evidence is presented here that such a mechanism 
can be employed for antigen presentation to HLA-A2-re- 
stricted T  cells. 
Materials  and Methods 
Cells and Viruses.  The B lymphoblastoid cell line 721.45 and 
its derivative  721.174 (gift of R. DeMars, University of Wisconsin, 
Madison, WI) have been described (18). Mutant 721.174 has a 
homozygous deletion of most of the MHC class II region (19). 
Recombinant vaccinia viruses Vac-M1 (gift of B. Moss, National 
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sity,  Oxford, UK) have been described (20,  21). Vac-H3-D and 
Vac-H3-J were constructed as follows.  The plasmid  p3X31A + (a 
gift from M. J. Gething, University of Texas Southwestern Med- 
ical Center, Dallas, TX) encoding the H3 hemagglutinin of influenza 
A virus was digested with either SalI (filled with dCTP and dTTP 
with Klenow polymerase) (H3-D) or BamHI (H3-J) and with EaeI. 
EaeI cuts the H3 coding region exactly at the signal sequence-mature 
H3 protein boundary, leaving a glycine residue at the NH2 ter- 
minus. BamHI cuts the H3 coding region exactly at the lumenal- 
transmembrane region boundary. SalI cuts in the vector 3' down- 
stream of the H3 coding region. The plasmid pEL1 (22) was digested 
with BgllI (for H3-D and H3-J), filled with dATP and dGTP (only 
for H3-D),  and with Sail.  The oligonucleotides TCGATAATT- 
CTATTAATCATGGCAGGCATCCTAGGCTTCGTCTTCACG- 
CTGGCTGCAGCTGCAGCT  and  GGCCAGCTGCAGCTG- 
CAGCCAGCGTGAAGACGAAGCCTAGGATGCCTGCCATGA- 
TTAATAGAATTA  were synthesized using  standard  automated 
procedures, purified on a 8% polyacrylamide gel,  annealed,  and 
ligated to the H3 fragment generated above and to the plasmid 
pEL1 in a triple ligation reaction. These oligonucleotides will pro- 
vide 14 bp of the 5' untranslated region of H3 and a 17-amino acid 
peptide (MAGILGFVFTLAAAAAG) that includes the HLA-A2- 
restricted epitope GILGFVFTL from the influenza A virus matrix 
protein  M1  (23).  The last  glycine residue is  part  of the EaeI- 
compatible end. The algorithm of yon Heijne (24) was used  to 
predict the putative signal  sequence  cleavage site. The 5' end of 
the annealed oligonucleotides had a Sail-compatible end for liga- 
tion to the Sail site of pEL1. The 3' end of the annealed oligonucle- 
otides had an EaeI-compatible end for ligation to the EaeI site of 
the H3 fragment. The 3' end of the H3 fragment was either BamHI 
(H3-J) or Sail (for H3-D) for ligation to the BgllI site of pEL1. 
SalI and BgllI ends were made compatible by partial filling as de- 
scribed  above. In the construct H3-J, the stop codon is provided 
by the vector after a serine  residue,  pEL1-H3-D and pEL1-H3-J 
were used to generate recombinant vaccinia viruses  as described 
(25). Vac-H3-C was constructed as follows. The oligonucleotides 
TCGAAGGCATCCTAGGATTCGTATTTACACTCA  and TCG- 
ATGAGTGTAAATACGAAq~CTAGGATGCCT  were annealed and 
ligated to the unique XhoI site of the p3X31A § plasmid.  XhoI 
cuts the coding sequence of H3 at residue 411 of the mature H3 
protein. These oligonucleotides encode an 11-amino acid peptide 
(EGILGFVFTLI) that includes the M1 epitope GILGFVFTL. The 
flanking residues  glutamic acid and isoleucine originate from the 
duplication of the XhoI site during the construction. This modified 
plasmid was digested as described for H3-D. The oligonucleotides 
TCGAGCAAAAGCAGGGGATAATTCTATTAATCATGAAG  and 
GCK2  C CTI'CATGATTAATAGAATTATC  C C C'IGC  T T T TGC were 
annealed and ligated to the modified H3 fragment generated as 
above and to the plasmid  pEL1 generated as described for H3-D. 
These oligonucleotides provide 29 bp of the 5' untranslated region 
of H3 and the first two residues of the H3 coding region (MK) 
and an EaeI-compatible end that encodes a glycine residue.  The 
resulting plasmid pEL1-H3-C was used to generate recombinant 
vaccinia virus as described (25). Recombinant vaccinia viruses were 
purified on a sucrose gradient as described (25). All these constructs 
are represented schematically (see Fig.  1). 
Immunoprecipitations.  2  x  106 721.45 cells were infected with 
30 PFU/cell of vaccinia viruses at 4~  for 1 h in 0.5 ml serum-free 
medium, and further incubated on a rotator for I h at 37~  The 
infected cells were then starved in methionine-free medium for 1 h, 
and labeled with 50/~Ci [3SS]methionine for 15 min. Cells were 
then washed twice in Tris-saline buffer (10 mM Tris-HC1, pH 7.5, 
150 mM NaC1) and lysed in the same buffer containing 2% Triton 
X-100, 0.5 mM PMSF, 5 mM iodoacetamide, and 0.1 mM N-p- 
tosyl-t-lysylchloromethyl  ketone. The lysate was then centrifuged 
at lO,O00g for 5 rain, at 4~  The supernatant was first precleared 
with a control mouse ascites and a polyclonal anti-mouse IgG anti- 
serum bound to protein A-Sepharose (all from Sigma Chemical Co., 
St. Louis, MO). The specific immunoprecipitation was performed 
with a pool of mAbs against H3 (gift of R. Webster, St. Jude Chil- 
dreffs Research  Hospital, Memphis,  TN). 
Flow Cytometry.  106 cells were infected as described above. At 
the end of the incubation at 37~  in serum-free medium, FCS was 
added to a final concentration of 5% and the cells were incubated 
for 3 h  at 37~  Cells  were then washed twice with PBS sup- 
plemented with 2% FCS and incubated with the anti-H3 mAbs 
in the same buffer. The cells were then washed twice and incubated 
with a FITC-conjugated goat anti-mouse Ig antibody (Tago Inc., 
Burlingame, CA) in the same buffer. The cells were then washed 
twice, fixed in 1% paraformaldehyde in PBS, and analyzed on a 
FACScan  |  cytometer (Becton Dickinson & Co., Mountain View, 
CA). 
Cytotoxicity Assays.  5  x  105 721.45 and 721.174 cells were in- 
fected as described above but incubated for 2 h at 37~  in the 5% 
FCS medium. Cells were labeled with 50 #Ci sodium [SlCr]chro- 
mate for 1 h in 0.2 ml, washed, counted, and plated at 5  x  103 
cells/well in V-bottom 96-well plates containing previously aliquoted 
effector cells. 
Results and Discussion 
The HLA-A2-restricted MI Epitope Can Serve as a Signal 
Sequence  Signal sequences do not contain specific amino acid 
residues  other  than  a  hydrophobic  stretch  of about  eight 
residues (24). Cleavage usually occurs after a small nonpolar 
residue located five to  six amino  acids  downstream  of the 
hydrophobic segment. Thus,  it appears that a hydrophobic 
peptide corresponding to a T  cell epitope may fulfill the re- 
quirement  to serve as a signal sequence.  To test this possi- 
bility, the signal sequence of the influenza virus hemagglu- 
tinin protein H3 was replaced by a sequence containing the 
HLA-A2-restricted epitope of the influenza virus matrix pro- 
tein M1 (residues 58-66). The nine amino acid-long epitope 
(GILGFVFTL) was preceded by the initiator methionine and 
an alanine residue and was followed by a spacer of five ala- 
nines (Fig.  1). According to the predictive algorithm of yon 
Heijne (24), signal peptidase would deave after the last ala- 
nine residue of the spacer or after the adjacent  glycine res- 
idue,  yielding a peptide  of 16 or  17  residues,  respectively. 
Synthetic DNA corresponding to this  17 amino  acid-long 
extension was added to the coding region of the mature H3 
molecule (construct H3-D),  as well as to a truncated form 
of H3 lacking the transmembrane region and cytoplasmic tail 
(construct  H3-J).  The M1  epitope was also inserted into a 
cytosolic form of the H3 molecule (H3-C in Fig.  1).  Con- 
structs encoding these chimeric molecules were inserted into 
recombinant  vaccinia viruses. 
To determine whether the 17 amino acid-long extension 
could serve as a signal sequence, ceils infected with recombinant 
vaccinia viruses were metabolically labeled with [35S]methi- 
onine and  H3 molecules analyzed by SDS-PAGE after im- 
munoprecipitation (Fig. 2). A nonglycosylated cytosolic form 
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Figure  1.  Diagram of recombinant hemagglutinin H3 molecules.  The 
wild-type H3 molecule  (H3) comprises  a leader sequence  of 16 amino acids 
(open box), a lumenal domain of 513 amino acids (solid  line), a transmem- 
brane domain of 26 amino acids (filled box), and a cytoplasmic  tail of 11 
amino acids (solid  line). Construct D was produced by replacing the native 
leader sequence  by the indicated amino acids. Construct J carries the same 
modification as construct D with,  in addition, a deletion of the trans- 
membrane domain and the cytoplasmic  tail. Construct C was produced 
by substituting the native leader sequence with amino acids MKG and 
by inserting the 11 indicated amino acids at position 411 of the leaderless 
H3 molecule.  GILGFVFTL  is a HLA-A2-restricted  epitope from the ma- 
trix M1 protein. 
of H3 has  an apparent  molecular weight  of '~62,000  (22). 
Cells  infected with  Vac-H3-C  produced a  molecule of the 
expected size (Fig. 2 b). Due to a high number of glycosyla- 
tion sites, the H3 molecule translocated into the ER appears 
as  a precursor with  a molecular weight  of ~83,000.  Cells 
infected with Vac-H3 produced a molecule of the expected 
size (22, and Fig. 2 d). It is interesting to note that the product 
of Vac-H3-D was indistinguishable  from that of Vac-H3 in 
both size and amount,  suggesting  that the H3-D molecule 
was efficiently translocated into the ER (Fig. 2 c).  Further- 
more, the product of Vac-H3-J migrated slightly faster (Fig. 
2 e) as expected for a glycosylated molecule lacking 34 amino 
acids of the transmembrane  region and cytoplasmic tail.  It 
is worth noting that cells infected with Vac-H3-D did not 
produce detectable cytosolic H3-D molecules. Cytosolic H3-D 
molecules, which would migrate at the level of H3-C, were 
not  seen even after long  exposures  of the  gels.  Unless  the 
half-life of a  cytosolic H3-D  is  much  shorter than  that  of 
cytosolic H3-C,  this result suggests  that translocation into 
the  EtL  mediated  by  the  artificial  leader  sequence  is  very 
efficient. In pulse-chase studies (data not shown), the cyto- 
solic H3-C molecule displayed a half-life of ,,ol  h, whereas 
the H3 and  H3-D  molecules were much more stable.  The 
truncated  molecule  H3-J  appeared  in  the  cell  supernatant 
during the chase, showing that it was secreted after translo- 
cation into  the EtL. 
Proper folding of H3 molecules is a requirement for their 
transport  out  of the ER  and  through  the Golgi apparatus 
to the cell surface (26). To determine whether the H3-D mol- 
ecule fulfilled this requirement, cell surface levels of H3 mol- 
ecules were analyzed by flow cytometry on cells infected for 
4  h  with Vac-H3  and Vac-H3-D  (Fig.  3).  Surface levels of 
H3-D (Fig. 3 b) were similar to those of H3 molecules (Fig. 
3 d). In contrast,  H3-C molecules were undetectable at the 
cell surface (Fig. 3 e). These data demonstrate that H3 mole- 
cules translocated into the EtL via the artificial signal sequence 
containing the M1 epitope are transported to the cell surface 
in a form recognizable by mAbs and in amounts comparable 
to H3 molecules expressed with their native signal sequence. 
Surface expression of H3-J molecules was  also detected, al- 
though  at  reduced levels (Fig.  3  c).  Such cell-bound  trun- 
cated H3  molecules may represent  secreted molecules  that 
bind to cells via interaction of the H3 globular domain with 
sialic acid residues. 
HLA-A2-restricted  T Cells Recognize a Peptide Derived  from 
a Signal Sequence.  To test whether a cleaved signal sequence 
may be a source ofpeptide for presentation to class I-restricted 
T  cells,  it is necessary to use cells deficient in  the classical 
Figure  2.  Synthesis of different hemagglutinin molecules in cells in- 
fected  with recombinant vaccinia  viruses, The B cell  line 721.45 was either 
uninfected (a) or infected  with Vac-H3-C (b), Vac-H3-D (c), Vac-H3 (d), 
and Vac-H3-J (e) at 30 PFU/cell. After 2 h,  cells were labeled with 
[3sS]methionine for 15 min, lysed, and H3 molecules  were immunopre- 
cipitated with a pool of mAbs specific for H3,  separated on a 10.5% 
polyacrylamide-SDS gel, and  autoradiographed. Mr  x  10 -3  for  14C- 
labeled markers are indicated on the right. 
Figure  3.  Cell  surface  expression  of different  hemagglutinin molecules 
in cells infected  with recombinant vaccinia  viruses. The B cell line 721.45 
was either uninfected (a) or infected with Vac-H3-D (b), Vac-H3-J (c), 
Vac-H3 (d), and Vac-H3-C (e) at 30 PFU/cell for 4 h. Cells were placed 
on ice and analyzed  for surface  expression  of H3 molecules  by flow cytom- 
etry after staining with a pool of mAbs specific for H3. (Shaded  areas) 
Fluorescence obtained with the secondary antibody alone. 
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for class I-restricted presentation is extremely efficient, such 
that even minute amounts of cytosolic signal sequences could 
lead to detectable recognition by T cells. To avoid this possi- 
bility, the mutant B cell line 721.174 was used. This B-LCL 
carries  a deletion of the entire class II region of the MHC 
that includes the TAP1 and TAP2 genes (27).  721.174 cells 
pulsed with synthetic peptide M1 58-66  were lysed by the 
HLA-A2-restricted T cell line Q157 (Fig. 4 a). No lysis oc- 
curred with cells infected with a control vaccinia virus Vac-H3 
(Fig. 4 b).  Cells infected with Vac-M1 and with Vac-H3-C 
were lysed very inefficiently by Q157 (Fig.  4,  c and d).  In 
contrast, presentation of the M1 epitope within the signal 
sequence of H3-D and H3-J molecules was very efficient (Fig. 
4, e andJ~. The lack of presentation of M1 and H3-C mole- 
cules is not due to poor expression in infected cells, because 
the Vac-M1 and Vac-H3-C viruses  led to good protein ex- 
pression  (Fig.  2 and data not shown), and because  721.45 
cells (with normal expression of TAP and large multifunc- 
tional protease [LMP] genes) infected with Vac-M1 and Vac- 
H3-C were recognized by the T  cell line Q157  (Fig.  5). 
The data presented here demonstrate that insertion of the 
M1 epitope at the NH2 terminus of the H3 molecule leads 
to the presentation of this signal sequence-derived  epitope 
to  HLA-A2-restricted  T  cells.  There  are  essentially two 
pathways of processing that could lead to presentation of this 
peptide. First, precursor molecules which fail to be translo- 
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Figure 4.  Presentation  of the M1 epitope to HLA-A2-restricted  T cells. 
Lysis  by the Ml-specific  T cell line Q157 of 721.174 cells that were either 
pulsed with the synthetic  peptide M1 58-66 at 50 #g/ml (a) or infected 
for 3 h with 3 PFU/cell (squares) or 10 pfu/cell (triangles) of Vac-H3 (b), 
Vac-M1 (c), Vac-H3-C (d), Vac-H3-D (e), and Vac-H3-J ~. 
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Figure  5.  TAP is required for the presentation of the M1 epitope to 
HLA-A2-restricted  T cells when the epitope is processed in the cytosol, 
but not when  it is derived  from  a signal  sequence. Lysis  by the Ml-specific 
T cell  line  Q157 of 721.45 cells (a) and 721.174 (b) infected  with 3 PFU/cell 
of Vac-H3 (1-13), Vac-M1 (M1), Vac-H3-C (C), Vac-H3-D (D), and Vac- 
H3-J (]). Each  bar represents the average  of  two separate  experiments.  The 
data are expressed as relative  lysis (percentage  of specific lysis  divided  by 
percentage of lysis with a saturating  amount  of peptide) at an E/T ratio 
of 1 in experiment 1, and 0.33 in experiment 2. Lysis  of cells pulsed  with 
50 #g/ml of synthetic  peptide  M1 58-66 was 26 and 34% for 721.45, and 
89 and 71% for 721.174, in the two experiments. 
cared into the EtL may be processed in the cytosol and follow 
the classical class I presentation pathway. Although formally 
possible, it is unlikely that cytosolic processing accounts for 
the results presented here because 721.174 cells expressing an 
exclusively cytosolic form of antigen (M1 or H3-C) did not 
present the epitope, whereas cells expressing ER-translocated 
forms (H3-D and H3-J),  with undetectable levels of cyto- 
solic antigen, did. The second possibility is that the signal 
peptidase-mediated cleavage of the leader sequence in the ER 
provides  a substrate for binding to HLA-A2. Trimming of 
such peptides to an optimal size for binding to HLA-A2 is 
not efficient, as peptides eluted from HLA-A2 molecules in 
721.174 cells were heterogeneous in length, from 9 to 13 amino 
acids (11, 12). HLA-A2 molecules can bind some of these 
longer peptides with high affinity (28). Presentation of pep- 
tides derived from signal sequences is based either on the ability 
of T  cells to recognize longer peptides bound to HLA-A2 
or, more likely, to trimming of these peptides to the usual 
length. A biochemical characterization of peptides eluted from 
HLA-A2 in cells expressing H3-D molecules would not re- 
solve this question, because it would only reveal the predom- 
inant forms of peptides, whereas T cells may selectively recog- 
nize a subset of appropriately-sized peptides. 
In  summary, the data presented here  show  that  signal 
sequence-derived  peptides can serve as a source  of epitopes 
for T cells. This mechanism may be useful for immune sur- 
veillance, particularly of cells that fail to utilize the classical 
1992  HLA-A2-restricted  Presentation of a Signal Sequence class I pathway, such as tumor cells (29) or cells infected by 
certain viruses (30). The high prevalence of HLA-A2 (~40% 
among Caucasians) may be due to the propensity of this class 
I  allele  to  bind  hydrophobic  peptides,  including  signal 
sequence-derived peptides that, as shown here, can be presented 
to T  cells. 
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